Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,571.20 +0.73%
EUR-USD 1.2517 -0.1227%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 90.86 +0.22%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: NASDAQ CM
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

BioLine RX Ltd

Add to Portfolio

BLRX:US

2.5100 USD 0.0300 1.18%

As of 20:10:00 ET on 05/25/2012.

Snapshot for BioLine RX Ltd (BLRX)

Open: 2.5400 Day's Range: 2.4200 - 2.5400 Volume: 12,100 Bid: 2.4700
Previous Close: 2.5400 52wk Range: 2.3800 - 6.8700 1-Yr Rtn: - Ask: 2.5100

Stock Chart for BLRX

No chart data available.
  • BLRX:US 2.5100
  • 1D
  • 1M
  • 1Y
2.5400
Interactive BLRX Chart

Previous Close

Key Statistics for BLRX

Current P/E Ratio (ttm) -
Estimated P/E (-) -
Earnings Per Share () (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 44.19
Shares Outstanding (M) 17.61
Enterprise Value (M ILS) (ttm) -
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 08/28/2012
More BLRX Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for BLRX

  • Revenue
  • Net Income (M/ILS)
  • Profit Margin (%)
More BLRX Income Statement Data
  • Total Assets
  • Total Liabilities (M/ILS)
  • Debt to Assets (%)
More BLRX Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/ILS)
More BLRX Cash Flow Data

Company Profile & Key Executives for BLRX

BioLineRx Ltd. is a biopharmaceutical development company. The Company develops clinical-stage therapeutic pharmaceutical drugs.

Aharon SchwartzChairmanKinneret Livnat SavitskyChief Executive Officer
Philip SerlinCFO/COONir GamlielVP:Business Development
More Company Profile & Key Executives for BLRX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements